|
| | Issue Date | Title | Author(s) |
| 1 | Sep-2007 | Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial | Patil, S.T.; Zhang, L.; Martenyi, F.; Lowe, S.L. ; Jackson, K.A.; Andreev, B.V.; Avedisova, A.S.; Bardenstein, L.M.; Gurovich, I.Y.; Morozova, M.A.; Mosolov, S.N.; Neznanov, N.G.; Reznik, A.M.; Smulevich, A.B.; Tochilov, V.A.; Johnson, B.G.; Monn, J.A.; Schoepp, D.D. |
| 2 | Jun-2012 | Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: Pooled results from 10 phase 1 studies | Ayan-Oshodi, M.; Wondmagegnehu, E.T.; Lowe, S.L. ; Kryzhanovskaya, L.; Walker, D.J.; Kinon, B.J. |
| 3 | Dec-2010 | Cortisol response to individualised graded insulin infusions: A reproducible biomarker for CNS compounds inhibiting HPA activation | Chen, C.L.H.; Willis, B.A.; Mooney, L.; Ong, G.K.; Lim, C.N.; Lowe, S.L. ; Tauscher-Wisniewski, S.; Cutler Jr, G.B.; Wiss, S.D. |
| 4 | Feb-2012 | Effects of a novel mGlu 2/3 receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid | Lowe, S. ; Dean, R.; Ackermann, B.; Jackson, K.; Natanegara, F.; Anderson, S.; Eckstein, J.; Yuen, E.; Ayan-Oshodi, M.; Ho, M.; McKinzie, D.; Perry, K.; Svensson, K. |
| 5 | Jul-2005 | Hemodynamic effects of acute administration of atomoxetine and methylphenidate | Kelly, R.P.; Yeo, K.P. ; Teng, C.-H.; Smith, B.P.; Lowe, S. ; Soon, D.; Read, H.A.; Wise, S.D. |
| 6 | May-2006 | L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI | Lowe, S.L. ; Poo Yeo, K.; Teng, L.; Soon, D.K.W.; Pan, A.; Wise, S.D.; Peck, R.W. |
| 7 | Feb-2006 | Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction | Yeo, K.P. ; Lowe, S.L. ; Lim, M.T.; Voelker, J.R.; Burkey, J.L.; Wise, S.D. |
| 8 | 16-Nov-2011 | Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor | May, P.C.; Dean, R.A.; Lowe, S.L. ; Martenyi, F.; Sheehan, S.M.; Boggs, L.N.; Monk, S.A.; Mathes, B.M.; Mergott, D.J.; Watson, B.M.; Stout, S.L.; Timm, D.E.; LaBell, E.S.; Gonzales, C.R.; Nakano, M.; Jhee, S.S.; Yen, M.; Ereshefsky, L.; Lindstrom, T.D.; Calligaro, D.O.; Cocke, P.J.; Greg Hall, D.; Friedrich, S.; Citron, M.; Audia, J.E. |
| 9 | Nov-2004 | Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection | Soon, D.K.W.; Lowe, S.L. ; Teng, C.H.; Yeo, K.P. ; McGill, J.; Wise, S.D. |
| 10 | Jun-2012 | Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants | Willis, B.A.; Zhang, W.; Ayan-Oshodi, M.; Lowe, S.L. ; Annes, W.F.; Sirois, P.J.; Friedrich, S.; De La Peña, A. |
| 11 | Jan-1996 | The mammalian ARF-like protein 1 (Arl1) is associated with the Golgi complex | Lowe, S.L. ; Wong, S.H. ; Hong, W. |
